TABLE 5.
Operative outcome.
| N = 30 | |
|---|---|
| Age, year, median (range) | 56 (34–73) |
| Sex, male, n (%) | 20 (66.7) |
| Diagnosis, thymic carcinoma, n (%) | 23 (76.7) |
| Time between surgery and end of neoadjuvant therapy, day, median (range) | 44 (10–130) |
| Thymectomy type, n (%) | |
| Total thymectomy | 28 (93.3) |
| Partial thymectomy | 2 (6.7) |
| Resected structures, n (%) | |
| Lung | 22 (73.3) |
| Diaphragm | 14 (46.7) |
| Pericardium | 25 (83.3) |
| Innominate vein | 23 (76.7) |
| Phrenic nerve | 12 (40.0) |
| Complete resection, n (%) | 25 (83.3) |
| Pathological Masaoka‐Koga stage, n (%) | |
| Pathological CR | 1 (3.3) |
| I | 0 (0.0) |
| II | 7 (23.3) |
| III | 15 (50.0) |
| VI | 7 (23.3) |
| Pathological TNM stage, n (%) | |
| Pathological CR | 1 (3.3) |
| I | 7 (23.3) |
| II | 3 (10.0) |
| III | 12 (40.0) |
| VI | 7 (23.3) |
| TRG score, n (%) | |
| 1 | 1 (3.3) |
| 2 | 6 (20.0) |
| 3 | 10 (33.3) |
| 4 | 12 (40.0) |
| 5 | 1 (3.3) |
| Adjuvant treatment, n (%) | |
| None | 18 (60.0) |
| Chemotherapy | 7 (23.3) |
| Radiotherapy | 4 (14.4) |
| Concurrent chemoradiotherapy | 1 (3.3) |
| Surgical specimen analyzed by Lunit SCOPE IO | N = 30 |
|---|---|
| Intratumoral TIL density (/mm2), median (range) | 374.99 (5.79–7415.21) |
| Stromal TIL density (/mm2), median (range) | 531.02 (96.75–1729.08) |
| Immune phenotype score (%), median (range) | |
| Inflamed | 37.7 (0.3–94.5) |
| Immune‐excluded | 18.5 (0.0–58.8) |
| Immune desert | 32.2 (2.3–96.1) |
| Immune phenotype, n (%) | |
| Inflamed | 20 (66.7) |
| Immune‐excluded | 2 (6.7) |
| Immune desert | 8 (26.7) |
Abbreviations: CR, complete response; TIL, tumor‐infiltrating lymphocyte; TRG, tumor regression grade.